Johnson & Johnson (JNJ)

NYSE · Drug Manufacturers - General

259.24
+2.26 (+0.88%)
Updated Aug 8, 2:13 PM ET
AI Rating
Buy
Overall Score
75
Trend
97
Momentum
39
Risk
89

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Jul 22, 2025 260 sessions Aug 3, 2026

AI Analysis

Johnson & Johnson is trading at $259.24, up 0.88% on the session. The 50 day average sits at $245.68 and the 200 day at $226.75, which puts the stock in a uptrend. RSI is at 48.8, which reads as neutral, and MACD is bearish crossover. Volume is below average.

The nearest support is around $246.05 with resistance near $269.43, so that band frames the current range. Average daily movement is roughly $6.43, or about 2.5% of the share price, which is what any stop placement has to allow for. The overall health score of 75 out of 100 combines a trend score of 97, momentum of 39 and a risk score of 89.

Technical indicators

RSI (14)
48.8
neutral
MACD
3.249
bearish crossover
SMA 20
257.48
SMA 50
245.68
SMA 200
226.75
uptrend
ATR (14)
6.43
avg daily range
Support
246.05
Resistance
269.43
Volume vs 20d
0.43x
below average
Volatility
27.1%
annualised
1 month
-3.77%
3 months
+11.42%

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.